We exist to bring meaningful medicines to patients quickly & safely.
BridgeBio is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. It has a late-stage investigational pipeline including Acoramidis for ATTRv, BBP-418 for LGMD2I/R9, Encaleret for ADH1 and hypoparathyroidism, Infigratinib for achondroplasia and hypochondroplasia, and BBP-812 for Canavan Disease.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2025
Jan 2024
Mar 2020
Jun 2019
Jan 2019
Sep 2017
Create a free account to see which investors have funded this company.
Create Free AccountAI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Long-read DNA sequencing company providing advanced systems for complete and accurate genome, tra...
